Abstract: A device (1) for connecting an electric power source (8) with an electric appliance (9) comprising a first electric coil (4), connecting the electric power source (8) with the device (1) and a second electric coil (5), connecting the electric appliance (9) with the device (1), at least one sensor (6) arranged outside the device (1) for identifying a speed of air, an alarm device connected to the at least one sensor (6) configured such that depending on the speed of air generates a pre-alarm signal and/or a main alarm signal and/or cuts an electric connection between the electric power source (8) and the electric appliance (9), and an electric circuit having an input element (7) configured such that by operating the input element (7) after the end of a preset period of time, the electric connection between the electric power source (8) and the electric appliance (9) is activated, if the at least one sensor (6) does not identify a preset speed of air.

Abstract: A device (1) for connecting an electric power source (8) with an electric appliance (9) comprising a first electric coil (4), connecting the electric power source (8) with the device (1) and a second electric coil (5), connecting the electric appliance (9) with the device (1), at least one sensor (6) arranged outside the device (1) for identifying a speed of air, an alarm device connected to the at least one sensor (6) configured such that depending on the speed of air generates a pre-alarm signal and/or a main alarm signal and/or cuts an electric connection between the electric power source (8) and the electric appliance (9), and an electric circuit having an input element (7) configured such that by operating the input element (7) after the end of a preset period of time, the electric connection between the electric power source (8) and the electric appliance (9) is activated, if the at least one sensor (6) does not identify a preset speed of air.

Abstract: The invention relates to probiotic micro-organisms isolated from faeces of children exclusively fed with breast milk. Said microorganisms are used in the food or pharmaceutical industry, especially for use in infant formula milk, due to their probiotic properties which have beneficial effects on the health of those ingesting them. Said microorganisms consist of Lactobacillus rhamnosus HERO 22A (CNCM I-4036), Lactobacillus paracasei HERO 7 (CNCM I-4034) and Bifidobacterium breve HERO 15B (CNCM I-4035).

Abstract: The invention relates to probiotic micro-organisms isolated from feces of children exclusively fed with breast milk. Said microorganisms are used in the food or pharmaceutical industry, especially for use in infant formula milk, due to their probiotic properties which have beneficial effects on the health of those ingesting them. Said microorganisms consist of Lactobacillus rhamnosus HERO 22A (CNCM I-4036), Lactobacillus paracasei HERO 7 (CNCM I-4034) and Bifidobacterium breve HERO 15B (CNCM I-4035).

Abstract: The invention relates to probiotic micro-organisms isolated from faeces of children exclusively fed with breast milk. Said microorganisms are used in the food or pharmaceutical industry, especially for use in infant formula milk, due to their probiotic properties which have beneficial effects on the health of those ingesting them. Said microorganisms consist of Lactobacillus rhamnosus HERO 22A (CNCM I-4036), Lactobacillus paracasei HERO 7 (CNCM I-4034) and Bifidobacterium breve HERO 15B (CNCM I-4035).

Abstract: This invention relates to a functional food supplement, specifically intended to supplement the enteral or oral nutrition of patients with neurological or neurodegenerative alterations, and for the prevention of cognitive or behaviour disorders, especially in the case of elderly persons, where the functional ingredient especially conceived for the nourishment of patients suffering from, or prone to neurological or neurodegenerative alterations, cognitive deterioration or behaviour disorders comprises a mixture of UMP (uridine monophosphate or uridine) and/or IMP (inosine monophosphate or inosine), vitamins of the B group (B1, B6, B9 and B7), phospholipids and gangliosides and sialic acid, as well as a large amount of DHA.

Abstract: The present invention relates to a complete food product for specific nutritional use, especially intended for enteral or oral nutrition of patients who suffer neurological or neurodegenerative alterations, and for the prevention of cognitive or behaviour disorders, especially in the case of elderly persons, such food product comprising a functional ingredient especially conceived for the nourishment of patients suffering from, or prone to neurological or neurodegenerative alterations, cognitive deterioration or behaviour disorders, as well as a mixture of carbohydrates, a mixture of proteins, a mixture of lipids and dietary fibre, inulin, vitamins and minerals.

Abstract: The invention relates to probiotic micro-organisms isolated from faeces of children exclusively fed with breast milk. Said microorganisms are used in the food or pharmaceutical industry, especially for use in infant formula milk, due to their probiotic properties which have beneficial effects on the health of those ingesting them. Said microorganisms consist of Lactobacillus rhamnosus HERO 22A (CNCM I-4036), Lactobacillus paracasei HERO 7 (CNCM I-4034) and Bifidobacterium breve HERO 15B (CNCM I-4035).

Abstract: The present invention is related to a new mixture of carbohydrates and its usage for the preparation of a food product intended for oral or enteral nutrition, particularly for the nutrition of the diabetic patient and in particular for the nutrition of the diabetes type II patient and their associated comorbidity. The carbohydrate mixture of the present invention is formed by type IV or RS IV (modified maltodextrins) resistant starch, maltodextrin of low dextrose equivalent DE=5-8, preferably DE equal to 6, insulin and cellulose and is exempt from fructose.

Abstract: This invention relates to a novel protein mixture and the use thereof in the preparation of a food product intended for oral or enteral nutrition. This protein mixture, based on caseinate, pea proteins and milk serum proteins has very high protein quality indices (protein efficiency index) and a good digestibility, thus the ease of conversion of said protein mixture is very good when compared to that of superior-quality highly-digestible proteins per excellence.

Abstract: This invention relates to a novel mixture of lipids and the use thereof for preparing a food product intended for oral or enteral nutrition wherein the lipid mixture has a balanced and adequate fatty acid profile specially suited for using the same in complete nutritional products for oral or enteral administration. Such fatty acid profile, from vegetable and fish oils, provides a relatively low content of saturated fatty acids, a high content of medium-chain and monounsaturated fatty acids (oleic acid) and a balanced supply of essential (linoleic and ?-linolenic) fatty acids, as well as long-chain polyunsaturated fatty acids of the Omega 3 series (n-3).

Abstract: This invention relates to a food product for enteral or oral nutrition, comprising a novel protein mixture, a novel lipid mixture, as well as carbohydrates, soluble and insoluble fibre, vitamins and minerals, composing a nutritional product adequate for pathologic conditions where there is some kind of impairment to meet nutritional needs with a normal oral diet.

Abstract: Process for the preparation of ground cereal based foods and food products obtained thereby. The process comprises an initial phase of toasting all the cereals used and a hydrolyzation phase with amylolytic enzymes of the toasted cereals. The food products obtained have better organoleptic and hygienic properties, improved dispersibility, and allow reduction in the amount of edulcorants to be added.

Abstract: A nucleotide enriched humanized milk for infant nourishment, which is manufactured as a sterilized fluid or an instant powdered milk, both of which contain nucleotides AMP, CMP, GMP, IMP and UMP at concentrations similar to those found in human milk. The remaining components of this humanized milk comply with the standards of EPSGAN and AAP. The concentrations of nucleotides referred to in powdered milk are: 1.12 mg/100 g of CMP; 1.32 mg/100 g of AMP; 1.49 mg/100 g of GMP; 3.42 mg/100 g of UMP and 0.45 mg/100 g of IMP. The nucleotidic composition of fluid milk is: 0.15 mg/100 ml of CMP; 0.17 mg/100 ml of AMP; 0.19 mg/100 ml of GMP; 0.44 mg/100 ml of UMP and 0.06 mg/100 ml of IMP. The raw materials used in the manufacture of this humanized milk, cow's milk, demineralized whey, lactose, vitamins and minerals, are mixed and pasteurized. The nucleotides are added afterwards and the new mix is UHT-sterilized or spray-dried.